AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11865843
Drug: Rapid dipstick
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid dipstick assay for the detection of Salmonella typhi‐specific IgM antibodies
Trial: 7793871
Drug: Cefodizime (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (50 mg/kg once daily for 10 +/- 3 days)
Trial: 7793871
Drug: Ceftriaxone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (50 mg/kg once daily for 10 +/- 3 days)
Trial: 7196564
Drug: Photocoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photocoagulation treatment
Trial: 29468508
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 0.25% bupivacaine plus tizanidine 6 mg capsule (Group SC+T)
Trial: 29468508
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 0.9% saline plus oral placebo (Group C)
Trial: 21901320
Drug: Donepezil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (0.5 mg/kg)
Trial: 21901320
Drug: Donepezil (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (1.0 mg/kg)
Trial: 21901320
Drug: Scopolamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.3 mg)
Trial: 11120963
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate 120 mg by injection (group 1 and group 2)
Trial: 11120963
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate 240 mg by infusion (group 3)
Trial: 8137478
Drug: 4'-epidoxorubicin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4'-epidoxorubicin (70 mg) alone (group A)
Trial: 8137478
Drug: Lipiodol emulsion
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol emulsion with 4'-epidoxorubicin (70 mg) (group B)
Trial: 26031368
Drug: Neoadjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant capecitabine combined with oxaliplatin (CAPOX) followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab.
Trial: 24378824
Drug: Urinary calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary calprotectin concentrations in bladder cancer patients (522.3 ng/ml)
Trial: 24378824
Drug: Calprotectin concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calprotectin concentrations in low grade tumors (351.9 ng/ml)
Trial: 21899798
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei ssp. paracasei (L. casei 431®)
Trial: 17126335
Drug: Oxiplex/AP gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex/AP gel treatment (treated group)
Trial: 10592423
Drug: Parenteral fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral fluids with diazepam
Trial: 10592423
Drug: Parenteral fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral fluids without diazepam (control group)
Trial: 1765205
Drug: PGE2 pessaries
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 pessaries (2.5 mg) 1‐2 a day
Trial: 1765205
Drug: PGE2 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 (0.5 mg) in a viscous intracervical gel once daily
Trial: 31780429
Drug: Back massage
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back massage (twice per day in the morning and evening)
Trial: 28176487
Drug: Lornoxicam Immediate-Release
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam Immediate-Release Tablets (8 mg/tablet)
Trial: 17687149
Drug: Weekly bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly bolus CPT‐11 plus FU plus LV
Trial: 17687149
Drug: Weekly bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly bolus FU plus LV (control)
Trial: 14694457
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg bid (Ta)
Trial: 14694457
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg bid plus PFME (Tp)
Trial: 11405384
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg nabumetone
Trial: 9990362
Drug: Cyclosporin at
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin at an initial dose of 1 mg/kg per day
Trial: 17613971
Drug: Residential Treatment
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential Treatment (RT)
Trial: 23670354
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg daily for 12 weeks
Trial: 19473604
Drug: Brethmol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brethmol (4 mg)
Trial: 19473604
Drug: Ventolin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin (4 mg)
Trial: 14982045
Drug: Dorzolamide 2%/Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2%/Timolol 0.5% combination (COSOPT) eye drops twice daily
Trial: 14982045
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% (XALATAN) eye drops once daily
Trial: 31911179
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera (MO) 400 mg/kg body weight
Trial: 31911179
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera hard gelatin capsules
Trial: 28805348
Drug: Levocarnitine administered
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocarnitine administered 0 and 30 min before each hemodialysis session
Trial: 28805348
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 0 and 30 min before each hemodialysis session
Trial: 23601628
Drug: Exercise prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise prescription based on physical fitness test results and personal choice
Trial: 21480939
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) combined with oral hygiene instructions (OHI)
Trial: 21480939
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions (OHI) alone
Trial: 19797730
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (DXM) 40 mg/day for four consecutive days
Trial: 14760910
Drug: Control (Dentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Dentin chips obtained before treatment)
Trial: 1732569
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of 11 mg/kg of amikacin every 12 hours
Trial: 31425751
Drug: 1-step: 2-h,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-step: 2-h, 75 g, oral glucose tolerance test (OGTT)
Trial: 31425751
Drug: 2-step: 1-h,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-step: 1-h, 50 g glucose challenge test (GCT) followed by 3-h, 100 g OGTT if GCT-positive
Trial: 28737128
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of oseltamivir 75-mg capsule
Trial: 28737128
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation Tamiflu®
Trial: 27566367
Drug: Adalimumab with
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab with azathioprine (25-100mg daily)
Trial: 25332331
Drug: Hypocaloric nutritional
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric nutritional support (50% of calculated daily caloric requirement of 25-30 kcal · kg(‐1) · d(‐1))
Trial: 25332331
Drug: Eucaloric nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucaloric nutritional support (standard calculated daily caloric requirement of 25-30 kcal · kg(‐1) · d(‐1))
Trial: 19930005
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine o.d.
Trial: 17966778
Drug: New graduated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New graduated dilator with a standard treatment schedule (20 patients)
Trial: 17966778
Drug: Multiple anal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple anal dilators (20, 23, 27 mm) with a standard treatment schedule (20 patients)
Trial: 17966778
Drug: New graduated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New graduated dilator according to a free treatment schedule (20 patients)
Trial: 17966778
Drug: Graduated anal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graduated anal dilator according to a free treatment schedule
Trial: 30734085
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg calcium supplement
Trial: 25943912
Drug: Conventional Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Care (CC-1)
Trial: 25943912
Drug: Conventional Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Care (CC-2)
Trial: 18323492
Drug: Constraint‐induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐induced movement therapy
Trial: 22221683
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group (n = 40): 1 mL (10 mg) nalbuphine diluted with 1 mL lidocaine (20 mg)
Trial: 22221683
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group (control) (n = 40): 1 mL (10 mg) nalbuphine diluted with 9 mL normal saline
Trial: 12752837
Drug: Multifactorial fall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial fall prevention program (staff education, environmental adjustment, exercise, drug review, aids, hip protectors, postfall problem-solving conferences)
Trial: 9193126
Drug: Self-directed treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed treatment with minimal therapist contact (five meetings, readings, self-directed exposure with response prevention)
Trial: 9193126
Drug: Waiting period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting period (6-week delay before treatment)
Trial: 1735279
Drug: bid dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid dosing (4 inhalations bid)
Trial: 1735279
Drug: qid dosing
RxNorm normalized name: MINOXIDIL 5 g in 100 mL / BIOTIN 5 g in 100 mL EXTRACORPOREAL AEROSOL, FOAM [QIDILA 5% Minoxidil Foam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qid dosing (2 inhalations qid)
Trial: 26381054
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg at steady state
Trial: 26381054
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptive (OC) alone (reference)
Trial: 23354115
Drug: Teriparatide (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (daily subcutaneous injection of 20 μg)
Trial: 23354115
Drug: Bisphosphonate (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate (daily oral administration of 2.5 mg of risedronate)
Trial: 23354115
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without medication for osteoporosis)
Trial: 7042888
Drug: Fresh concentrated
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh concentrated Egyptian liquid BCG vaccine (2 mg/ml) given in gradually increasing doses.
Trial: 7042888
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (11 patients) did not receive any further treatment after chemotherapy.
Trial: 30446398
Drug: Drug-Eluting Stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stents (DES) with longer DAPT (>6 months)
Trial: 30446398
Drug: Drug-Eluting Stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stents (DES) with shorter DAPT
Trial: 28771493
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (LNS) 20g daily
Trial: 23829890
Drug: nab-P 260
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 260 mg/m(2) q3w with bevacizumab 15 mg/kg q3w
Trial: 23829890
Drug: nab-P 260
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 260 mg/m(2) q2w with filgrastim and bevacizumab 10 mg/kg q2w
Trial: 23829890
Drug: nab-P 130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-P 130 mg/m(2) weekly with bevacizumab 10 mg/kg q2w
Trial: 20890204
Drug: Tinnitus retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus retraining therapy (TRT) with acoustic stimulation devices and 3 months of individual counseling
Trial: 20890204
Drug: General counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General counseling without additional sound therapy
Trial: 9699090
Drug: Increased urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urinary albumin excretion (UAE)
Trial: 8120515
Drug: Selenium and
RxNorm normalized name: Selenium and/or selenium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium and vitamin E treatment (1.6 mg selenium and 800 mg vitamin E daily for 4 months)
Trial: 8120515
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (corresponding number of placebo tablets)
Trial: 2680285
Drug: Fenticonazole ovule
RxNorm normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenticonazole ovule (600 mg)
Trial: 2680285
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablet (500 mg)
Trial: 1106277
Drug: Azathioprine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (3 to 4 mg/kg of body weight) plus prednisone (60 mg per day initially)
Trial: 1106277
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg per day initially)
Trial: 24445089
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of backward walking exercise and alpha-lipoic acid (ALA) treatment (ALA for 2 weeks, backward walking exercise for 12 weeks)
Trial: 24445089
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) treatment (control group)
Trial: 24445089
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of backward walking exercise and alpha-lipoic acid (ALA) treatment
Trial: 16304254
Drug: Nasal or
RxNorm normalized name: Panasal Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal or inhaled beclomethasone dipropionate (BDP) administered separately or in combination for 16 weeks after a 2-week placebo run-in period
Trial: 10981083
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment to a diastolic blood pressure of less than or equal to 80 mm Hg
Trial: 10981083
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment to a blood pressure goal of less than 150/85 mm Hg
Trial: 10981083
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment to the lowest diastolic blood pressure goal of less than or equal to 80 mm Hg
Trial: 8551116
Drug: Rice paper
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice paper patch
Trial: 1983509
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - Embolex‐LM, n = 464
Trial: 1983509
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (Liquemin), n = 452
Trial: 1983509
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - Sandoparin, n = 298
Trial: 1983509
Drug: Standard heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin, n = 296
Trial: 25773496
Drug: GSK256073 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 (all doses)
Trial: 19169102
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (simple shoulder sling)
Trial: 17222813
Drug: Enalapril (E(+):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (E(+): 10 mg/day)
Trial: 17222813
Drug: Losartan (L(+):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (L(+): 50 mg/day)
Trial: 17222813
Drug: Enalapril +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril + Losartan (E(+)L(+): 10 mg/day + 50 mg/day)
Trial: 17222813
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (E(-)L(-))
Trial: 15563440
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day iron supplementation
Trial: 9241004
Drug: Bupropion 100
RxNorm normalized name: buPROPion 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 100 mg three times daily
Trial: 8347437
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg od)
Trial: 8347437
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg od)
Trial: 3521559
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 micrograms/kg, single oral dose)
Trial: 3521559
Drug: Diethylcarbamazine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (administered for eight days)
Trial: 30047223
Drug: Closed-loop (CL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop (CL) insulin pump delivery
Trial: 30047223
Drug: Threshold-low-glucose-suspend (TLGS)
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold-low-glucose-suspend (TLGS) insulin pump delivery
Trial: 21862166
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Sulphonylureas
Trial: 17124817
Drug: Wound bed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound bed preparation
Trial: 14531593
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.5 mol/L aqueous solution of CaCl2 followed by 1.0 mol/L aqueous K3PO4
Trial: 14531593
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1.0 mol/L aqueous solution of KCl followed by distilled water
Trial: 11003455
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/day for 3 days)
Trial: 8840843
Drug: Fish oils
RxNorm normalized name: fish oils
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oils (5.4 g n‐3 fatty acids)
Trial: 8840843
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (30 mg SC BID)
Trial: 1309968
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of ASA